Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
United StatesIPO:
28 March 2022Website:
http://www.conduitpharma.comNext earnings report:
14 May 2025Last dividends:
N/ANext dividends:
N/APrice
pre-market | 7 min agoDividend
Analysts recommendations
Institutional Ownership
CDT Latest News
NAPLES, Fla. and CAMBRIDGE, United Kingdom, Nov. 21, 2024 (GLOBE NEWSWIRE) -- Conduit Pharmaceuticals Inc. (Nasdaq: CDT) ("Conduit Pharmaceuticals" or "Conduit" or the “Company”) today announced that the Japan Patent Office (JPO) has granted approval of a composition of matter patent application for the Company's lead asset, AZD1656, a Glucokinase Activator targeting a wide range of autoimmune disorders.
SAN DIEGO and LONDON, Nov. 04, 2024 (GLOBE NEWSWIRE) -- Conduit Pharmaceuticals Inc. (Nasdaq: CDT ) (“Conduit” or the “Company”), today announces the filing of two new patent applications relating to its lead clinical candidate, AZD1656, a HK-4 glucokinase activator licensed from AstraZeneca targeting a broad spectrum of autoimmune disorders.
SAN DIEGO and LONDON, Nov. 01, 2024 (GLOBE NEWSWIRE) -- Conduit Pharmaceuticals Inc. (Nasdaq: CDT ) (“Conduit” or the “Company”), today announced the restructuring of a portion of its financial obligations, enhancing its balance sheet and liquidity. The Company has restructured the $2.65 million loan note with Nirland Limited (“Nirland”) and secured $1.2 million in new promissory notes through separate agreements with third parties.
Conduit Pharmaceuticals (NASDAQ: CDT ) stock is up on Wednesday following a shareholder update concerning a major investor in the company. New filings with the Securities and Exchange Commission (SEC) reveal that Nirland Limited holds a 14.8% stake in CDT stock.
Initial joint project in Fuzhou expected to generate an increase in revenue by more than 50% over next three years Initial joint project in Fuzhou expected to generate an increase in revenue by more than 50% over next three years
Three Phase Project Will Process 400,000 Tons/Day and Has Initial Contract Value of 1.16B RMB Three Phase Project Will Process 400,000 Tons/Day and Has Initial Contract Value of 1.16B RMB
SHENZHEN, China, May 20, 2024 (GLOBE NEWSWIRE) -- CDT Environmental Technology Investment Holdings Limited (NASDAQ: CDTG) (“CDT”), a leading provider of waste treatment systems and services throughout China, today announces that it has filed its annual report on Form 20-F for the fiscal year ended December 31, 2023 with the U.S. Securities and Exchange Commission (the “SEC”) on May 15, 2024. The annual report on Form 20-F, which contains CDT's audited consolidated financial statements, can be accessed through the SEC's website at www.sec.gov or CDT's website at https://www.cdthb.cn.
The U.S. House of Representatives passed a bill on March 13 that stated a requirement for ByteDance, a reputable Chinese tech company, to ban TikTok in the United States. The legislation, now known as the Protecting Americans from Foreign Adversary Controlled Application Act , was forwarded by the U.S. government Reps.
Conduit Pharmaceuticals (NASDAQ: CDT ) stock is rocketing higher on Monday despite a lack of news from the biopharmaceutical company. There are no new press releases or filings with the Securities and Exchange Commission (SEC) that explain why CDT stock is rising today.
Conduit just began trading on the Nasdaq on Sept. 25. The company focuses on advancing other pharmaceutical companies' deprioritized assets.
What type of business is Conduit Pharmaceuticals?
Conduit Pharmaceuticals Inc., a clinical-stage specialty biopharmaceutical company, develops pharmaceutical products that provides unmet medical needs in the areas of autoimmune diseases and idiopathic male infertility. Its pipeline includes AZD1656, which has completed Phase I trials for the treatment of type 2 diabetes, renal transplant, Hashimoto's thyroiditis and Grave's disease, uveitis, and preterm labor; and AZD5904, which has completed Phase I clinical trials for the treatment of idiopathic male infertility. The company was founded in 2019 and is based in San Diego, California. Conduit Pharmaceuticals Limited is a subsidiary of Corvus Capital Limited.
What sector is Conduit Pharmaceuticals in?
Conduit Pharmaceuticals is in the Healthcare sector
What industry is Conduit Pharmaceuticals in?
Conduit Pharmaceuticals is in the Biotechnology industry
What country is Conduit Pharmaceuticals from?
Conduit Pharmaceuticals is headquartered in United States
When did Conduit Pharmaceuticals go public?
Conduit Pharmaceuticals initial public offering (IPO) was on 28 March 2022
What is Conduit Pharmaceuticals website?
https://www.conduitpharma.com
Is Conduit Pharmaceuticals in the S&P 500?
No, Conduit Pharmaceuticals is not included in the S&P 500 index
Is Conduit Pharmaceuticals in the NASDAQ 100?
No, Conduit Pharmaceuticals is not included in the NASDAQ 100 index
Is Conduit Pharmaceuticals in the Dow Jones?
No, Conduit Pharmaceuticals is not included in the Dow Jones index
When was Conduit Pharmaceuticals the previous earnings report?
No data
When does Conduit Pharmaceuticals earnings report?
The next expected earnings date for Conduit Pharmaceuticals is 14 May 2025